Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25918190 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL15018797 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL5989437 | 0.93 | GPR119 (0.48) | GPR119KDM4EMAPTTHRBHPGD | |
| SCHEMBL30503427 | 0.90 | CHRM2 (0.41) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL20689796 | 0.87 | CHRM2 (0.41) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL16716889 | 0.83 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119KDM4E | |
| SCHEMBL3744023 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL21452961 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL433051 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL6504804 | 0.82 | KDM1A (0.44) | CHRM2CHRM1CHRM3GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4525987-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119546575-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119013274-A | PRMT5 inhibitor, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024156938-A1 | CBL-B INHIBITORS | ORION CORPORATION (FI) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024021957-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| US-20080207695-A1 | Thrombin Inhibiting 2-Oxo-1,2,5,6-Tetrahydropyridine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008045250-A1 | MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| EP-1893601-A1 | THROMBIN INHIBITING 2-OXO-1, 2, 5, 6-TETRAHYDROPYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1891036-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | University of Florida Research Foundation, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070099962-A1 | 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| CN-1894214-A | New 5,6-dihydropyrin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| WO-2006135323-A1 | THROMBIN INHIBITING 2-OXO-1, 2, 5, 6-TETRAHYDROPYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006133303-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1697323-A1 | NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058826-A1 | NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CHRM2 3019/4885CHRM1 3350/4885CHRM3 3384/4885 |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | IL17A, IL15, IL18 | CHRM2 4776/4885CHRM1 4592/4885CHRM3 4851/4885 |
| US-20080207695-A1 | Thrombin Inhibiting 2-Oxo-1,2,5,6-Tetrahydropyridine Derivatives | F2R, F2, SERPINE1 | CHRM2 905/4885CHRM1 412/4885CHRM3 2444/4885 |
| US-20070099962-A1 | 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin | F2, SERPINC1, SERPINE1 | CHRM2 1972/4885CHRM1 1122/4885CHRM3 3550/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | CHRM2 894/4885CHRM1 654/4885CHRM3 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.